OBJECTIVES: Multiple signaling proteins may be aberrantly activated and/or overexpressed in pancreatic tumors, including the nonreceptor protein tyrosine kinase Src. The goal of this study was to determine the role of Src in regulating VEGF expression and angiogenic potential in pancreatic cancer cell lines. METHODS: Src activity was inhibited using the Src family kinase selective inhibitor PP2, and c-Src expression was down-regulated via siRNA. The activities of downstream signaling molecules phosphatidyl inositol 3'-kinase (PI3K) and p38 mitogen-activated protein kinase (MAPK) were disrupted via selective inhibitors. In vivo angiogenesis was assessed through the use of a gel-foam assay. RESULTS: Inhibition of Src activity or expression decreases both constitutive and EGF-induced VEGF production. Both the PI3K/Akt and p38 MAPK pathways are activated in a Src family kinase-dependent fashion on EGF-R activation and are important for EGF-mediated VEGF production in pancreatic cancer cells. Additionally, media from Src-inhibited L3.6pl cells fail to promote angiogenesis into gel foams implanted subcutaneously into mice, whereas media from control cells promote a robust angiogenic response. CONCLUSIONS: Src activity contributes to constitutive and EGF-induced VEGF expression and angiogenic potential in pancreatic cancer cells. Therefore, Src may be a viable target for antiangiogenesis therapy in pancreatic cancer.
OBJECTIVES: Multiple signaling proteins may be aberrantly activated and/or overexpressed in pancreatic tumors, including the nonreceptor protein tyrosine kinase Src. The goal of this study was to determine the role of Src in regulating VEGF expression and angiogenic potential in pancreatic cancer cell lines. METHODS:Src activity was inhibited using the Src family kinase selective inhibitor PP2, and c-Src expression was down-regulated via siRNA. The activities of downstream signaling molecules phosphatidyl inositol 3'-kinase (PI3K) and p38 mitogen-activated protein kinase (MAPK) were disrupted via selective inhibitors. In vivo angiogenesis was assessed through the use of a gel-foam assay. RESULTS: Inhibition of Src activity or expression decreases both constitutive and EGF-induced VEGF production. Both the PI3K/Akt and p38 MAPK pathways are activated in a Src family kinase-dependent fashion on EGF-R activation and are important for EGF-mediated VEGF production in pancreatic cancer cells. Additionally, media from Src-inhibited L3.6pl cells fail to promote angiogenesis into gel foams implanted subcutaneously into mice, whereas media from control cells promote a robust angiogenic response. CONCLUSIONS:Src activity contributes to constitutive and EGF-induced VEGF expression and angiogenic potential in pancreatic cancer cells. Therefore, Src may be a viable target for antiangiogenesis therapy in pancreatic cancer.
Authors: Kyung Mi Lee; Ki Won Lee; Sung Keun Jung; Eun Jung Lee; Yong-Seok Heo; Ann M Bode; Ronald A Lubet; Hyong Joo Lee; Zigang Dong Journal: Biochem Pharmacol Date: 2010-07-01 Impact factor: 5.858
Authors: Niharika B Mettu; Donna Niedzwiecki; Christel Rushing; Andrew B Nixon; Jingquan Jia; Sherri Haley; Wanda Honeycutt; Herbert Hurwitz; Johanna C Bendell; Hope Uronis Journal: Cancer Chemother Pharmacol Date: 2019-03-20 Impact factor: 3.333
Authors: Jose G Trevino; Justin M Summy; Donald P Lesslie; Nila U Parikh; David S Hong; Francis Y Lee; Nicholas J Donato; James L Abbruzzese; Cheryl H Baker; Gary E Gallick Journal: Am J Pathol Date: 2006-03 Impact factor: 4.307
Authors: Jing Zhang; Serk In Park; Marlene C Artime; Justin M Summy; Ami N Shah; Joshua A Bomser; Andrea Dorfleutner; Daniel C Flynn; Gary E Gallick Journal: J Clin Invest Date: 2007-10 Impact factor: 14.808